We administered ketamine to schizophrenic individuals in a double-blind, placebo-controlled
design using a range of subanesthetic doses (0.1, 0.3, and 0.5 mg/kg) to evaluate the …

This study evaluates the effects of ketamine on healthy and schizophrenic volunteers (SVs)
in an effort to define the detailed behavioral effects of the drug in a psychosis model. We …

Background The adequacy of subjects' informed consent to research is the focus of an
important public and professional debate. The potential impairment of decisional capacity in …

Genes disrupted in schizophrenia may be revealed by de novo mutations in affected persons
from otherwise healthy families. Furthermore, during normal brain development, genes are …

The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in
subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, …

Regional cerebral blood flow (rCBF) data from two PET‐ 15 O water schizophrenia studies
were analyzed using individually placed, magnetic resonance (MR)‐guided hippocampal …

Several electrical neural oscillatory abnormalities have been associated with schizophrenia,
although the underlying mechanisms of these oscillatory problems are unclear. Animal …

Glioma is the most common malignant primary brain tumor. Its rapid growth is aided by
tumor-mediated glutamate release, creating peritumoral excitotoxic cell death and vacating space …

Importance Alterations in glutamatergic neurotransmission have been postulated to be a
key pathophysiologic mechanism in schizophrenia. Objective To evaluate hippocampal …

Medication management in schizophrenia is a lengthy process, as the lack of clinical response
can only be confirmed after at least 4 weeks of antipsychotic treatment at a therapeutic …